Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

484 results about "Acute toxicity testing" patented technology

Acute toxicity is distinguished from chronic toxicity, which describes the adverse health effects from repeated exposures, often at lower levels, to a substance over a longer time period (months or years). It is widely considered unethical to use humans as test subjects for acute (or chronic) toxicity research.

Preparation of functional area of sea purse blood vessel growth inhibition factor 1 and use of the functional area of sea purse blood vessel growth inhibition factor 1 in medicaments for preventing and curing tumors

The invention relates to the preparation of a functional area of a sea purse blood vessel growth inhibition factor 1 and the use of the functional area of the sea purse blood vessel growth inhibition factor 1 in medicaments for preventing and curing tumors. In the invention, a gene engineering technique is used to realize the cloning, expression and recombination of the sea purse blood vessel growth inhibition factor 1; the recombinant functional fragment of the sea purse blood vessel growth inhibition factor 1 has the bioactivities for resisting the growth of blood vessels, tumor growth, tumor transplantation, acute toxicity tests and stability tests; and the functional area of the sea purse blood vessel growth inhibition factor 1 can be mixed with or dissolved in pharmaceutically acceptable carriers to prepare the medicaments for curing various tumors. The functional area of the sea purse blood vessel growth inhibition factor 1 has high action specificity, has the characteristics of easy expression, low degradation rate and the like of gene engineering medicaments and has the effects of inhibiting blood vessel growth, tumor growth and tumor transplantation; the provided gene engineering technique can realize the industrial production of the functional area of the sea purse blood vessel growth inhibition factor 1; and the functional area of the sea purse blood vessel growth inhibition factor 1 prepared by the gene engineering technique can be used in the preparation of medicaments for inhibiting blood vessel growth and preventing and curing tumors.
Owner:GUANGDONG OCEAN UNIVERSITY

Avermectin microcapsule suspending agent and preparation method thereof

InactiveCN102106345AMeet the anti-efficacy requirementsReduce decompositionBiocideNematocidesAcute toxicity testingAdjuvant
The invention discloses an avermectin microcapsule suspending agent and a preparation method thereof. The avermectin microcapsule suspending agent mainly comprises the following components in percentage by weight: 1 to 10 percent of avermectin, 5 to 40 percent of solvent, 1 to 8 percent of capsule wall material, 0.1 to 3 percent of protection glue, 2 to 5 percent of emulsifier, 3 to 5 percent of dispersant, 0 to 14 percent of adjuvant, and the balance of water. The preparation method for the avermectin microcapsule suspending agent comprises the following steps of: preparing avermectin microcapsules from an avermectin active substance serving as capsule cores and a carbamide resin serving as the capsule wall material by using an interfacial polymerization technology, and finally blending to obtain a microcapsule water suspending agent. Active ingredients of the avermectin microcapsule suspending agent are centralized in the capsule cores, and other media are almost water, so the environmental pollution is reduced and the production cost of products is also effectively reduced. The avermectin microcapsule suspending agent has the release control capacity and can prolong effective duration of pesticides by 3 to 10 times, so that the acute toxicity of technical materials is reduced and the toxicity of a preparation on non-target organisms is also reduced. The avermectin microcapsule suspending agent is safe to use and transport.
Owner:联合国南通农药剂型开发中心 +1

Method for culturing mycelia and sporocarps of aweto

ActiveCN101843196ASolve the problem that cannot be cultivated on a large scaleHorticultureBiotechnologyAcute toxicity testing
The invention belongs to the technical field of fungus culture, particularly to a method for culturing mycelia and sporocarps of aweto, which solves the problem that artificial aweto in the prior art can not be cultured in a large scale. The method comprises the following steps of: selecting cephalosporium acremonium and Isaria cicadae; preparing a cephalosporium acremonium liquid strain and an Isaria cicadae liquid strain; preparing a solid culture medium from corn grit, soybean flour, wheat grains, sorghum grains, silkworm chrysalis meal, whole chicken eggs, black bean coarse powder containing hulls, degreased linseed oil and a nutrient solution, wherein the nutrient solution comprises chicken blood, pine needles, carrots, black beans and cattle bone; evenly mixing, and inoculating; and culturing to obtain the sporocarps and the mycelia. The detection indicates that the sporocarps contain at least 0.02% of adenosine and at least 0.1% of cordycepin, and the mycelia contain at least 0.055% of adenosine; the finger-print test result indicates that the degree of similarity of the sporophores and the mycelia is greater than 97%; and acute toxicity experiments and long-term toxicity experiments indicate that the sporophores and the mycelia have no toxicity and can be used as substitutes of natural aweto.
Owner:杨毅

Fungal fibrinolytic enzyme and cultivating method thereof

The invention discloses a fungal fibrinolytic enzyme and a preparation method thereof. The fungal fibrinolytic enzyme is prepared by taking a Cordyceps militaris strain as a strain and performing liquid fermentation culture, separation and purification. The relative molecular weight of the fibrinolytic enzyme is about 21,000. The Cordyceps militaris fibrinolytic enzyme has good thrombolytic performance, is free from obvious acute toxicity, has prospects for clinical trial, development and application, and adds a new member to a rare fibrinolytic enzyme family. Particularly, a preferable fibrinolytic-enzyme Cordyceps militaris strain C.LSG-1 obtained through severe screening is rough in growth conditions, short in enzyme production cycle and capable of harvesting a large amount of Cordyceps militaris mycelium during enzyme production, and is the strain excellent in production performance. The Cordyceps militaris fibrinolytic enzyme is an extracellular enzyme which is particularly beneficial to subsequent separation and purification during preparation. The fungal fibrinolytic enzyme takes corn protein with extensive sources as a main culture medium, thereby having low cost for raw materials and providing a novel way for developing and utilizing the prior resources.
Owner:QIQIHAR UNIVERSITY

Technique for preparing verbascoside with function of curing chronic glomerulonephritis in glutinous rehmannia leaf

InactiveCN101121740ANon-toxic and safeConducive to extensive clinical applicationEsterified saccharide compoundsSugar derivativesAcute toxicity testingDigitalis
The invention belongs to the technological field of the Chinese medicine, particularly relating to an extraction and separation processes of the active ingredients with the active function of treating the chronic glomerulonephritis. The mullein indican is the active compound researched and developed for many years in our research institute; the mullein indican is extracted, separated and refined from the digitalis leaf and is an active compound with the function of treating the chronic glomerulonephritis. The invention is the research result of many years held and developed by the Chinese Medicine Research Department of the Chinese Medicine Research Institute of China and is supported by the special fund of the Central Institute of the National Science and Technology Department; now the compound has been approved by the State Food and Drug Administration Bureau as the novel drug and the mechanism research of the treatment of the chronic nephritis has been completed; the pre-clinical research work includes the main pharmacodynamic experiment, the production technology experiment (including the industrialized extraction and separation processes), the quality control standard, the experiment of the affecting factors of the quality, the experiment of the long-term stability, the acute toxicity of the rat, the experiment of the long-term toxicity, the teratogenic and mutagenic experiment, the general pharmacological experiment, the pharmacokinetics experiment, and so on. The digitalis leaf is mainly produced in the Huaiqing area of the Henan province, and is also grown wild and cultivated in the Shaanxi, Hebei and other places of China.
Owner:INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI

High-efficiency cyhalothrin microcapsule suspension and preparation method thereof

InactiveCN105076188AMeet the anti-efficacy requirementsReduce decompositionBiocideAnimal repellantsNon target organismControlled release
The invention relates to a microcapsule suspension, the high-efficiency cyhalothrin microcapsule suspension comprises the following components: 1-20% of high-efficiency cyhalothrin, 1-10% of a solvent, 1-8% of a capsule wall material, 0.1-3% of a protecting adhesive, 2-5% of an emulsifier, 3-5% of a dispersant, 0.01-14% of an adjuvant and 1-99% of water. The preparation method is characterized in that a high-efficiency cyhalothrin active substrate is taken as the capsule core, a polyurea resin is taken as the capsule wall material, an interfacial polymerization technology is used for preparing the high-efficiency cyhalothrin microcapsule suspension, and finally the cyhalothrin microcapsule suspension is prepared. The effective components in the cyhalothrin microcapsule suspension are concentrated in the capsule core, and other medium can be water, such that environmental pollution is reduced, and production cost is effectively reduced. The high-efficiency cyhalothrin microcapsule suspension has release controlling capability, pesticide lasting period can be prolonged by 3-10 times, acute toxicity of original medicine can be reduced, toxicity of the cyhalothrin microcapsule suspension on non-target organisms is also reduced, and the high-efficiency cyhalothrin microcapsule suspension is safe to use and transport.
Owner:南通联农佳田作物科技有限公司

Method for forecasting acute toxicity of organic compounds by building quantitative structure-activity relationship model with quantum chemistry method

InactiveCN103646180APredict toxicityChemical property predictionSpecial data processing applicationsMolecular orbital energyAb initio quantum chemistry methods
The invention discloses a method for forecasting the acute toxicity of organic compounds by building a quantitative structure-activity relationship model with a quantum chemistry method. The method fully geometrically optimizes compound structures by using a Gaussian procedure so as to obtain quantum chemistry parameters including molecular volume, relative molecular mass, highest occupied molecular orbital energy, lowest unoccupied molecular orbital energy, energy gaps of frontier molecular orbital, dipole moment, solvation energy, electron energy and the like; using the quantum chemistry parameters and a hydrophobicity parameter as structural descriptors; in combination with toxicity data, quantitative relationship equations between various structural descriptors and toxicity are established according to a written procedure based on partial least square stepwise linear regression to obtain the multiple correlation coefficient, F-test value and sum of squared residuals, and then the model is verified so as to guarantee the external predictive ability. Therefore, the method can quickly and effectively forecast the toxicity of organic compounds to be studied, and provide necessary basic data for risk assessment and supervision of chemicals.
Owner:SHANDONG UNIV

Medicinal food formula and medicinal edible preparation for preventing and treating hyperuricemia and gout

The invention belongs to the field of traditional Chinese medicines, relates to traditional Chinese medicines and health care preparations, and especially relates to a medicinal food formula and a medicinal edible preparation for preventing and treating hyperuricemia and gout. The medicinal edible preparation comprises traditional Chinese medicines or active ingredients of 10 to 80 parts of plantain seed and 10 to 80 parts of semen cuscutae. The medicinal edible preparation is prepared from extract of plantain seed and semen cuscutae, and auxiliary materials, and can be processed into tablets, pills, electuary, an oral liquid, a tea bag and a health-care food additive. An animal acute toxicity test and a sub-chronic toxicity test prove that the medicinal edible preparation is safe and has no toxic or side effect. A pharmacodynamic animal test proves that the medicinal edible preparation can obviously reduce blood uric acid and improve kidney uric acid crystallization and injuries. The medicinal edible preparation as a treatment drug or a health-care product can be used for patients suffering from hyperuricemia and gout, can obviously reduce a blood uric acid level and relieve gouty arthritis symptoms, and has good safety.
Owner:张清仲

Mushroom ferment pure protein with antineoplastic activity, extracting method and formulation

Disclosed is lentinus edodes fermented pure protein with anti-tumor activity as well as an extracting method and a preparation thereof. The protein is obtained through fermentation, salting-out, dialysis, drying and column chromatography of mycelia of lentinus edodes C91-3; the protein is light brown or earthy yellow powder which can be dissolved in water and has specific fragrance, the pH value of aqueous solution is 5.0 to 8.0, the molecular weight is 1 KD to 90 KD, and the protein contains 18 types of amino acids and various proteins. The experiment proves that in the anti-tumor experiment in vitro, the tumor restraining rate of the lentinus edodes fermented pure protein LFP91-3-A to H22 and S180 in 72 hours can achieve 59.93 percent and 80.13 percent; lentinus edodes fermented pure protein LFP91-3-A has an inducing effect on H22 cell telomerase of which the activity is obviously restrained and apoptotic. The tumor restraining rate of lentinus edodes fermented pure protein LFP91-3-B to S180 can achieve 76.7 percent; the experiment proves that the strain fermented pure protein has relatively strong effect of directly killing tumor cells. The lentinus edodes fermented pure protein has no toxic side effect through animal acute toxicity experiments and long-term toxicity experiments.
Owner:DALIAN MEDICAL UNIVERSITY

Pesticide film forming agent used for controlling diseases and insect pests of forest trees, and its preparation method

InactiveCN103960228ASolve difficultySolve technical problems such as easy loss of drug effectBiocideFungicidesDiseaseAcute toxicity testing
The invention provides a pesticide film forming agent used for controlling diseases and insect pests of forest trees, and its preparation method. The pesticide film forming agent comprises 0.5-10% of an active component, 0.5-10% of a film forming aid, 5-15% of a solvent, 5-15% of an aid and 50-80% of water; and the active component is one of or a mixture comprising several of tebuconazole, difenoconazole, propiconazole and emamectin benzoate. The drug film forming agent has a good control effect on the diseases and insect pests of the forest trees, has a low price, is convenient to use, and has a good control effect on the dry rot diseases of hickory trees, the canker of various trees, stalk longhorn beetles and bark beetles, leaf aphids, red spider mites and the like especially; the drug film forming agent reduces the active component volatilization and loss possibility and changes the release performance, so the residual period is prolonged, the drug dose and the dosing frequency are reduced; and the drug film forming agent reduces the toxicity of highly toxic pesticides, reduces the acute toxicity of pesticides, reduces the drift of the pesticides, and mitigates the pollution to the environment and the hazard to crops.
Owner:ZHEJIANG FORESTRY UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products